Publizoom

Gilead Sciences GmbH

Track this competitor Create a free account to be notified when it wins a contract.

Contracts won
4
Amount won alone
€216,000 excl. VAT
Shared contracts
2 (multi-supplier framework agreements)
Period
15 July 2026 – 22 October 2026

Its contracts coming to an end

So many opportunities to take over these contracts when they are re-tendered.

Planned endContractCurrent holderAmount
30 June 2028
re-tender around December 2027
Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V zu der Wirkstofffixkombination Sofosbuvir/Velpatasvir
AOK Baden-Württemberg framework agreement
Gilead Sciences GmbH
1 bid received
€216,000
31 August 2028
re-tender around March 2028
Vereinbarung nach § 130c Abs. 1 SGB V für das Arzneimittel Epclusa mit der Wirkstoffkombination Sofosbuvir/Velpatasvir
AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen framework agreement
Gilead Sciences GmbH
1 bid received
€0

Contracts won

DateContractBuyerAmount
22/10/2026 Acuerdo Marco para el suministro, respetuoso con el medio ambiente, de medicamentos de uso humano antivirales con destino a los centros del ámbito de la sanidad pública valenciana Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad €26,782,004
shared by 13
15/09/2026 Medicinali 26 Regione Autonoma della Sardegna €57,162,015
shared by 4
28/07/2026 Vereinbarung nach § 130c Abs. 1 SGB V für das Arzneimittel Epclusa mit der Wirkstoffkombination Sofosbuvir/Velpatasvir AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen €0
15/07/2026 Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V zu der Wirkstofffixkombination Sofosbuvir/Velpatasvir AOK Baden-Württemberg €216,000

Source: contract award notices published on TED (Publications Office of the European Union), above the EU thresholds. Contracts published only in Belgium are not included yet.